Skip to content
Sign up to receive our free weekday morning edition, and you'll never miss a scoop.
House appropriators are trying to claw their way back to relevancy — particularly when it comes to the next defense spending cycle.

Defense: Defense appropriators gear up for budget showdown

House appropriators are trying to claw their way back to relevancy — particularly when it comes to the next defense spending cycle.

Weakened by last year’s budget process and undermined by the Trump administration’s continued reliance on reconciliation to boost the Pentagon’s topline, defense appropriators are clamoring to reassert themselves this time around.

Subscripion logo

You're seeing a preview of our Premium+ Defense coverage. Read the full story by subscribing here.

Defense Defense Policy

Presented by AstraZeneca

The 340B program was created to help patients. Instead, it’s helping hospitals earn massive profits. The 340B Rebate Model Pilot uses rapid verification of existing data to prevent duplicate discounts, strengthening program transparency and efficiency. Urge HHS to implement the Rebate Model Pilot and ensure 340B functions as intended. Get the facts.

Editorial photos provided by Getty Images. Political ads courtesy of AdImpact.

Presented by AstraZeneca

The 340B program is supposed to help vulnerable patients—but without strong safeguards, it’s siphoning away funds that could be used for free and charitable medicine. The 340B Rebate Model Pilot improves program integrity, preventing duplicate discounts and strengthening accountability. Urge HHS to implement the pilot today. Learn why it matters.

Welcome to Punchbowl News AM! We're glad to have you here.

Want to get more of what you need? Share a bit more about yourself to help us tailor your reader experience.

Thank you for signing up!

Thank you for signing up!

 

We have sent you a confirmation email. Please follow the provided instructions to complete your sign-up.

Thank you for confirming! You are now subscribed to the Punchbowl News AM list.

You're subscribed! Welcome to the community.